Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
77.8M
-
Shares change
-
+178K
-
Total reported value, excl. options
-
$6.1B
-
Value change
-
+$34M
-
Put/Call ratio
-
0.25
-
Number of buys
-
112
-
Number of sells
-
-92
-
Price
-
$78.44
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q2 2021
254 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q2 2021.
Denali Therapeutics Inc. - Common Stock (DNLI) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.8M shares
of 145M outstanding shares and own 53.53% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (15.1M shares), Crestline Management, LP (8.14M shares), VANGUARD GROUP INC (7.64M shares), BlackRock Inc. (7.04M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.9M shares), Temasek Holdings (Private) Ltd (4.41M shares), GILDER GAGNON HOWE & CO LLC (2.84M shares), FMR LLC (2.67M shares), STATE STREET CORP (2.32M shares), and CREDIT SUISSE AG/ (1.97M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.